Compare SMBK & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMBK | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.6M | 663.6M |
| IPO Year | 2000 | 2009 |
| Metric | SMBK | IRWD |
|---|---|---|
| Price | $42.34 | $4.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $43.17 | $7.67 |
| AVG Volume (30 Days) | 47.7K | ★ 1.8M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 39.25 | ★ 1400.00 |
| EPS | ★ 2.98 | 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $17.59 | $57.95 |
| Revenue Next Year | $10.30 | $4.39 |
| P/E Ratio | ★ $14.10 | $31.07 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $30.45 | $0.55 |
| 52 Week High | $43.91 | $5.78 |
| Indicator | SMBK | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 67.03 |
| Support Level | $40.73 | $3.07 |
| Resistance Level | $43.31 | $5.67 |
| Average True Range (ATR) | 1.32 | 0.26 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 42.53 | 90.09 |
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.